Novel therapeutic targets to halt the progression of Parkinson’s disease: an in-depth review on molecular signalling cascades

[1]  Mei Zhang,et al.  Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  R. Singh,et al.  Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies , 2022, Frontiers in Pharmacology.

[3]  Tsu-Kung Lin,et al.  MiR-29a inhibits MPP + - Induced cell death and inflammation in Parkinson's disease model in vitro by potential targeting of MAVS. , 2022, European journal of pharmacology.

[4]  Ming Lu,et al.  Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease , 2022, Acta pharmaceutica Sinica. B.

[5]  P. Calabresi,et al.  Rabphilin-3A as a Novel Target to Reverse α-synuclein-induced Synaptic Loss in Parkinson's Disease. , 2022, Pharmacological research.

[6]  Jinyong Peng,et al.  Neuroprotective Effect of Dioscin against Parkinson’s Disease via Adjusting Dual-Specificity Phosphatase 6 (DUSP6)-Mediated Oxidative Stress , 2022, Molecules.

[7]  E. Fedele,et al.  MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases , 2022, International journal of molecular sciences.

[8]  Hai-bin Luo,et al.  α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[9]  Ori J. Lieberman,et al.  Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy. , 2022, Science advances.

[10]  J. Bai,et al.  TRPV4 contributes to ER stress and inflammation: implications for Parkinson’s disease , 2022, Journal of neuroinflammation.

[11]  M. Nishibori,et al.  Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson's disease. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  B. Sperlágh,et al.  The dualistic role of the purinergic P2Y12-receptor in an in vivo model of Parkinson's disease: signalling pathway and novel therapeutic targets. , 2021, Pharmacological research.

[13]  Dawn M. Toolan,et al.  A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy , 2021, Neurobiology of Disease.

[14]  M. Essa,et al.  Effects of Telmisartan, an AT1 receptor antagonist, on mitochondria-specific genes expression in a mouse MPTP model of Parkinsonism. , 2021, Frontiers in bioscience.

[15]  T. Langer,et al.  Metabolism and Innate Immunity Meet at the Mitochondria , 2021, Frontiers in Cell and Developmental Biology.

[16]  Jeffrey A. Cohen,et al.  Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions , 2021, The Lancet.

[17]  Aijuan Yan,et al.  The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease , 2021, Experimental Neurology.

[18]  A. Kuhad,et al.  IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson's disease. , 2021, Neurotoxicology.

[19]  B. Singh,et al.  Promising drug targets and associated therapeutic interventions in Parkinson’s disease , 2021, Neural regeneration research.

[20]  Cao-Qi Lei,et al.  TAK1-TABs Complex: A Central Signalosome in Inflammatory Responses , 2021, Frontiers in Immunology.

[21]  M. Olianas,et al.  Valproic acid upregulates the expression of the p75NTR/sortilin receptor complex to induce neuronal apoptosis , 2020, Apoptosis.

[22]  M. Pallàs,et al.  Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy , 2020, Biomolecules.

[23]  K. Kang,et al.  Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson’s Animal Model , 2020, Molecular Imaging and Biology.

[24]  Long-Jun Wu,et al.  Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Zhijun Zhou,et al.  HMGB1 Mediates Paraquat-Induced Neuroinflammatory Responses via Activating RAGE Signaling Pathway , 2019, Neurotoxicity Research.

[26]  R. Franco,et al.  Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra , 2019, Brain, Behavior, and Immunity.

[27]  Sang Min Park,et al.  Association of age-related macular degeneration on Alzheimer's or Parkinson's disease: a retrospective cohort study. , 2019, American journal of ophthalmology.

[28]  Y. Yanagawa,et al.  Temperature elevation in epileptogenic foci exacerbates epileptic discharge through TRPV4 activation , 2019, Laboratory Investigation.

[29]  Liang-jie Yuan,et al.  G protein-coupled estrogen receptor is involved in the neuroprotective effect of IGF-1 against MPTP/MPP+-induced dopaminergic neuronal injury , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  E. Sidransky,et al.  Glucocerebrosidase and its relevance to Parkinson disease , 2019, Molecular Neurodegeneration.

[31]  J. Chen,et al.  Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy , 2019, Brain Research.

[32]  V. Medina,et al.  Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications , 2019, Front. Pharmacol..

[33]  Haitao Wang,et al.  Inhibition of PDE4 by FCPR16 induces AMPK‐dependent autophagy and confers neuroprotection in SH‐SY5Y cells and neurons exposed to MPP+‐induced oxidative insult , 2019, Free radical biology & medicine.

[34]  Zhiqiang Zhang,et al.  Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF‐&kgr;B signaling pathway in a mouse model of Parkinson's disease , 2019, Life sciences.

[35]  R. Gómez-Villafuertes,et al.  Dual-Specificity Phosphatase Regulation in Neurons and Glial Cells , 2019, International journal of molecular sciences.

[36]  J. Homberg,et al.  Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model , 2019, Brain, Behavior, and Immunity.

[37]  K. Hashimoto.  Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders , 2019, Front. Pharmacol..

[38]  S. Baratchi,et al.  The TRPV4 Agonist GSK1016790A Regulates the Membrane Expression of TRPV4 Channels , 2019, Front. Pharmacol..

[39]  S. Hwang,et al.  Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease , 2019, Neurotoxicology.

[40]  M. Heneka,et al.  Inflammasome signalling in brain function and neurodegenerative disease , 2018, Nature Reviews Neuroscience.

[41]  Jinbo Chen,et al.  P75 Involved in the Ubiquitination of α-synuclein in Rotenone-based Parkinson’s Disease Models , 2018, Neuroscience.

[42]  S. K. Trigun,et al.  Ambroxol modulates 6‐Hydroxydopamine‐induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms , 2018, Biochemical pharmacology.

[43]  P. Kosson,et al.  Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase , 2018, Neuropharmacology.

[44]  A. di Pardo,et al.  The S1P Axis: New Exciting Route for Treating Huntington's Disease. , 2018, Trends in pharmacological sciences.

[45]  Z. Andrews,et al.  Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease , 2018, Journal of Parkinson's disease.

[46]  A. Blokland,et al.  Phosphodiesterase 4 inhibition affects both the direct and indirect pathway: an electrophysiological study examining the tri-phasic response in the substantia nigra pars reticulata , 2018, Brain Structure and Function.

[47]  Haitao Wang,et al.  Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress , 2018, Redox biology.

[48]  F. Shi,et al.  Depletion of microglia augments the dopaminergic neurotoxicity of MPTP , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  Verónica García-Morales,et al.  The cAMP effectors PKA and Epac activate endothelial NO synthase through PI3K/Akt pathway in human endothelial cells , 2017, Biochemical pharmacology.

[50]  P. Calabresi,et al.  Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias , 2017, Neurobiology of Disease.

[51]  T. Dawson,et al.  c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential , 2017, Journal of Parkinson's disease.

[52]  David S. Park,et al.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.

[53]  Haitao Wang,et al.  FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects , 2017, Neuropharmacology.

[54]  S. Rai,et al.  Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model , 2017, Journal of Chemical Neuroanatomy.

[55]  J. Li,et al.  HMGB1 Mediates Autophagy Dysfunction via Perturbing Beclin1-Vps34 Complex in Dopaminergic Cell Model , 2017, Front. Mol. Neurosci..

[56]  X. Yang,et al.  Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission , 2017, Front. Neurosci..

[57]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[58]  H. Petry,et al.  Perspective on the Road toward Gene Therapy for Parkinson’s Disease , 2017, Front. Neuroanat..

[59]  J. Ma,et al.  Neuroprotective action of N-acetyl serotonin in oxidative stress-induced apoptosis through the activation of both TrkB/CREB/BDNF pathway and Akt/Nrf2/Antioxidant enzyme in neuronal cells , 2017, Redox biology.

[60]  Liu Yang,et al.  Neuroprotective effects of fingolimod in mouse models of Parkinson's disease , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  Lei Xiao,et al.  Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia , 2016, Cell Death and Differentiation.

[62]  C. Pittenger,et al.  Histamine regulation of microglia: Gene-environment interaction in the regulation of central nervous system inflammation , 2016, Brain, Behavior, and Immunity.

[63]  Raquel Ferreira,et al.  Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation , 2016, Journal of Neuroinflammation.

[64]  Zhe Wang,et al.  AMPK activation protects cells from oxidative stress‐induced senescence via autophagic flux restoration and intracellular NAD + elevation , 2016, Aging cell.

[65]  S. Rai,et al.  Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model , 2016, Journal of Chemical Neuroanatomy.

[66]  Archana Singh-Manoux,et al.  Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  C. Mulle,et al.  Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex , 2015, Nature Communications.

[68]  A. West,et al.  M1 and M2 immune activation in Parkinson’s Disease: Foe and ally? , 2015, Neuroscience.

[69]  S. Dheen,et al.  Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson’s disease and in MPP+-treated MN9D cells in vitro , 2015, Neuroscience.

[70]  P. Séguéla,et al.  P2Y12 expression and function in alternatively activated human microglia , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[71]  W. Chen,et al.  Plasma Insulin-Like Growth Factor 1 Is Associated with Cognitive Impairment in Parkinson's Disease , 2015, Dementia and Geriatric Cognitive Disorders.

[72]  M. Morissette,et al.  Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice , 2014, Neurobiology of Aging.

[73]  J. Strosznajder,et al.  The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson's disease. , 2014, Folia neuropathologica.

[74]  J. B. Arterburn,et al.  Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells. , 2014, ACS medicinal chemistry letters.

[75]  J. Strosznajder,et al.  Sphingosine Kinase 1 and Sphingosine-1-Phosphate in Oxidative Stress Evoked by 1-Methyl-4-Phenylpyridinium (MPP+) in Human Dopaminergic Neuronal Cells , 2014, Molecular Neurobiology.

[76]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[77]  D. Swaab,et al.  Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study , 2012, Neurobiology of Aging.

[78]  A. Rodriguez-Perez,et al.  Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease , 2012, Journal of Neuroinflammation.

[79]  R. Shaw,et al.  The AMPK signalling pathway coordinates cell growth, autophagy and metabolism , 2011, Nature Cell Biology.

[80]  R. Lu,et al.  β2-Adrenergic Receptor Activation Prevents Rodent Dopaminergic Neurotoxicity by Inhibiting Microglia via a Novel Signaling Pathway , 2011, The Journal of Immunology.

[81]  G. Pagès,et al.  The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. , 2010, American journal of physiology. Cell physiology.

[82]  Xin Wang,et al.  Protective effects of octacosanol on 6-hydroxydopamine-induced Parkinsonism in rats via regulation of ProNGF and NGF signaling , 2010, Acta Pharmacologica Sinica.

[83]  John H. Zhang,et al.  Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats , 2010, Stroke.

[84]  E. Degerman,et al.  Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. , 2009, Cellular signalling.

[85]  H. Lassmann,et al.  Pivotal Advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis , 2008, Journal of leukocyte biology.

[86]  C. Cahill,et al.  Interleukin (IL) 1β Induction of IL-6 Is Mediated by a Novel Phosphatidylinositol 3-Kinase-dependent AKT/IκB Kinase α Pathway Targeting Activator Protein-1* , 2008, Journal of Biological Chemistry.

[87]  Jing Chen,et al.  CSF‐1 receptor structure/function in MacCsf1r–/– macrophages: regulation of proliferation, differentiation, and morphology , 2008, Journal of leukocyte biology.

[88]  E. Schiffrin,et al.  Role of the renin-angiotensin system in vascular inflammation. , 2008, Trends in pharmacological sciences.

[89]  M. Beal,et al.  Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV , 2008, Experimental Neurology.

[90]  L. Snell,et al.  Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra , 2007, Molecular Neurodegeneration.

[91]  R. Thurmond,et al.  The histamine H4 receptor as a new therapeutic target for inflammation. , 2005, Trends in pharmacological sciences.

[92]  D. Feinstein,et al.  Norepinephrine protects cortical neurons against microglial‐induced cell death , 2005, Journal of neuroscience research.

[93]  F. Pixley,et al.  CSF-1 regulation of the wandering macrophage: complexity in action. , 2004, Trends in cell biology.

[94]  K. Tracey,et al.  HMGB1 as a DNA‐binding cytokine , 2002, Journal of leukocyte biology.

[95]  Kenji F. Tanaka,et al.  Existence of functional β1‐ and β2‐adrenergic receptors on microglia , 2002, Journal of neuroscience research.

[96]  H. Lother,et al.  The Angiotensin II AT2 Receptor Is an AT1Receptor Antagonist* , 2001, The Journal of Biological Chemistry.

[97]  J. Palacios,et al.  Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography Comparison with monkey and rat brain , 2000, Journal of Chemical Neuroanatomy.

[98]  T. Sasaki,et al.  Rabphilin-3A: A Multifunctional Regulator of Synaptic Vesicle Traffic , 1998, The Journal of general physiology.

[99]  Y. Kanai,et al.  Cloning and Functional Characterization of a System ASC-like Na+-dependent Neutral Amino Acid Transporter* , 1996, The Journal of Biological Chemistry.

[100]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[101]  Rohit Mantena.  The Critical Role of Glutamine Transporter ASCT2 in Parkinson’s Disease Progression , 2022 .

[102]  J. Homberg,et al.  Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like behaviour and pathology in a rat model , 2020 .

[103]  M. A. O’Neal,et al.  Neurology and Psychiatry of Women , 2019, Springer International Publishing.

[104]  M. Kelly.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. , 2018, Cellular signalling.

[105]  Hui-Ching Lin,et al.  Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress , 2017, Molecular Neurobiology.

[106]  A. Rodriguez-Perez,et al.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. , 2012, American journal of neurodegenerative disease.

[107]  J. Stockman.  Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[108]  J. Saba,et al.  Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. , 2010, Advances in enzyme regulation.

[109]  S. Pyne,et al.  Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. , 2009, Cellular signalling.

[110]  A. Segal,et al.  NADPH oxidase. , 1996, The international journal of biochemistry & cell biology.